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Abstract Although fingolimod is registered in Europe for
treatment of relapsing-remitting multiple sclerosis (RRMS)
if earlier disease modifying therapy (DMT) has failed, no
data regarding its efficacy in this patient group are avail-
able. This observational cohort study of the Neu-
roTransData network includes German RRMS outpatients
with failure of earlier therapy with injectable DMT
(iDMT), therefore switching to either another iDMT
(n = 133) or to fingolimod (n = 300). Statistical compar-
ison of clinical baseline characteristics showed more
severely affected patients in the fingolimod group. A
propensity-score matched group comparison was per-
formed (n = 99 in each group) covering more than 2-year
observation time. Fingolimod showed statistically signifi-
cant superior efficacy in comparison to iDMT regarding
annualized relapse rate (0.21 versus 0.33 per year), time-to-
relapse and likelihood of relapse (iDMT hazard ratio 1.7),
proportion and likelihood of patients with EDSS progres-
sion (15.10 versus 31.00 %; iDMT hazard ratio 1.7), per-
sistence on medication and likelihood of discontinuation
(iDMT hazard ratio 3.0). Significantly more patients were
free of relapse and EDSS progression with fingolimod than
with their second iDMT (64.4 versus 46.5 %, p\ 0.03).
This real-life evidence in German RRMS outpatients sup-
port data from controlled clinical studies and can quanti-
tatively support clinical decision finding processes if iDMT
therapy fails in RRMS.
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Introduction
Clinical studies of fingolimod leading to registration in
Europe showed superiority in clinical and MRI parameters
of RRMS patients in comparison to interferon-b-1a intra-
muscular (TRANSFORMS [1] and placebo (FREEDOMS
[2]). Based on safety concerns the market authorization by
EMA decided in March 2011 (ema.europa.eu/Find medi-
cine/Human medicines/European Public Assessment
Reports) that fingolimod should be given only if RRMS
patients had failed to respond to at least one other disease
modifying therapy or because their disease is getting worse
rapidly. Until 2011 only natalizumab was available if
injectable disease modifying therapies (iDMTs, Betaferon
interferon b-1b sc, Rebif interferon b-1a sc, Avonex
interferon b-1a im, Copaxone glatirameracetat, Extavia
interferon b-1b sc) failed with its specific benefit–risk
profile associated with cases of progressive multifocal
leukencephalopathy (PML) occurring since 2004. There-
fore up to 79 % of RRMS patients switched within iDMTs
in the US [3]. Although fingolimod offers a new treatment
option since 2011 for patients failing on iDMT therapy,
there is no known evidence regarding the efficacy of fin-
golimod in this particular clinical situation. This observa-
tional cohort study investigates the course of RRMS
patients with the failure of iDMT treatment, who either
switched within iDMT or to fingolimod.
Methods
This is an observational cohort study using health data
routinely collected in outpatient neurology practices
throughout Germany who are members of the Neu-
roTransData (NTD) network. Beside demographic data
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clinical parameters like relapses, EDSS and medication are
documented digitally in-time during clinical visits at least
once within 3-month periods in all patients with MS. All
neurologists are certified EDSS-rater. All participating
medical staff are trained to document these data in-time in
a standardized way in the web-based digital NTD data
source. This data acquisition protocol is approved by the
ethical committee of the Bavarian Medical Board (Bay-
erische Landesa¨rztekammer, 14.06.2012). The data are
pooled anonymously to form the database of the study.
This cohort analysis includes:
• RRMS patients with failure of iDMT therapy as judged
by the treating neurologist and the patient between
01.01.2010 and 30.06.2015,
• who switched either to another iDMT medication or to
fingolimod and,
• who had a documented observation period of a
minimum of 180 days.
The decision to switch and the choice of treatment were
at the discretion of the treating neurologist and the patient.
The primary outcome parameters were EDSS progres-
sion, relapse rate and adherence to medication. Progression
of EDSS was defined as an increase of the EDSS score by
one point if baseline EDSS was smaller than 5.5, or 0.5
points if baseline EDSS was equal or higher than 5.5.
Time-to-event analysis using Kaplan–Meyer survival
curves were calculated for time-to-progression, time-to
relapse and adherence including hazard ratios. Proportions
of patients free of progression and/or relapses were
calculated.
Patient population
The NTD database identified 1,472 RRMS patients
switching therapy. 433 of them fulfilled all inclusion cri-
teria with 300 patients switching to fingolimod and 133
within iDMT. 59.5 % of the 1,472 patients, almost com-
pletely switching within iDMT, had to be excluded because
the reason to switch was not treatment failure but others,
like adverse events. Comparing baseline characteristics of
clinical parameters of the fingolimod- and iDMT-cohort
statistical analysis identified significant differences as
shown in Table 1.
In this German outpatient cohort, RRMS patients
switching to fingolimod after failure of earlier iDMT
therapy had a significantly longer MS duration, showed
higher EDSS baseline scores, higher relapse rate and higher
proportion of patient suffering EDSS progression in the
previous year than patients switching within iDMT.
To enable a comparison of efficacy a propensity-score
matching was performed to define comparable cohort
groups. Patients were propensity score matched on EDSS
score and 3 months confirmed EDSS score when starting
on second therapy, number of relapses in the 360 days
before starting on second therapy and years since diagnosis
of RRMS. Variables considered for the propensity score
model but not included were: gender, region of birth, age,
and presence of relapse in the 361–720 days period before
starting second therapy (Table 2).
Results
Persistence on medication
Persistence on medication was significantly better in the
cohort with fingolimod compared to iDMT already from
the very beginning of therapy with persistence after 1 year
for fingolimod 95 % and iDMT 70 %, after 2 years 85 and
56 %, respectively (Fig. 1). Insufficient efficacy in about
11 times as many and side effects in about 50 % more
patients with iDMT therapy than with fingolimod were
causing discontinuation (Table 3).
Relapse rate
Annualized relapse rate and time-to-relapse analyses were
statistically significantly in favour of fingolimod (Figs. 2,
3, 4).
EDSS progression
The number of patients showing EDSS progression during
the observation time was significantly lower (p = 0.0231)
in the fingolimod cohort (n = 11; 15.10 %) than in the
iDMT cohort (n = 22; 31.00 %) (Tables 4, 5).
Cox proportional hazard models for matched
patients
Hazard ratios were higher for the cohort on iDMT com-
pared to fingolimod, reaching statistical significance for
persistence on medication and relapse.
Freedom of clinical disease activity: NEDA 2
The proportion of patients with/without evidence of clini-
cal MS disease activity regarding EDSS progression and/or
relapse was analyzed.
During treatment with fingolimod significantly more
patients remained free of relapses and EDSS progression
and fewer patients suffered from relapses and EDSS
progression.
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Discussion
This outpatient observational cohort study of German
RRMS patients demonstrates superiority of therapy with
fingolimod after failure of an earlier iDMT therapy
regarding persistence on medication, relapse rate and
EDSS progression compared to another medication within
iDMT therapies. Significantly more patients were free of
relapses and EDSS progression when treated with fin-
golimod compared to iDMT. This results in an impres-
sively better persistence on fingolimod medication than on
iDMT. The hazard ratios for patients switching within
iDMT showed a threefold risk for discontinuation of
medication and 1.7-fold risks for relapses and EDSS pro-
gression compared to fingolimod. In our matched popula-
tions the hazard ratio for discontinuation of iDMT
compared to fingolimod was even higher than in previously
published unmatched groups (NTD cohort hazard ratio
3.044 for iDMT versus glatirameracetat 1.75, interferon-1b
2.01 in [4]).
Overall data indicate that efficacy of fingolimod from
controlled studies can be replicated in real-life regarding
freedom of EDSS progression after 12 months [NTD: fin-
golimod 88 %, iDMT 80 %; TRANSFORM [1]:
Table 1 Clinical Characteristics of the total cohorts of patients when switching to fingolimod or another iDMT therapy due to failure of earlier
iDMT therapy
Characteristics Fingolimod cohort n = 300 iDMT cohort n = 133 p value
n % n %
Prior use of DMT before switching (n, % yes) 300 100.00 133 100.00
Glatiramer acetate 66 22.00 41 30.83
Interferon 234 78.00 92 69.17
Years since diagnosis (n, %)
Mean 8.23 5.5 \0.0001
95 % confidence interval 7.52–8.94 4.72–6.28
Standard deviation 6.22 4.52
Median 6 4
EDSS baseline score when switching (n, %)
Mean 2.51 1.91 0.0018
95 % confidence interval 2.32–2.69 1.62–2.20
Standard deviation 1.49 1.3
Median 2 2
EDSS progression in 1 year before switching (n, %) 45 15.00 8 66.00
Confirmed at least 3 months later 34 11.30 4 3.00
Confirmed at least 6 months later 31 91.20 3 75.00
Time since EDSS progression before switching
Mean 106.4 175.5 0.01796
95 % confidence interval 77.96–134.84 66.15–284.85
Standard deviation 94.67 130.79
Median 71 158
Relapses
% of patients with a relapse prior to switching (n, %) 254 84.70 83 62.40 \0.0001
Relapse within 90 days prior to switching 131 43.70 44 33.10 0.0384
Relapse within 180 days prior to switching 185 61.70 57 42.90 0.0003
Number relapses, 1–360 days prior to switching
0 79 26.30 61 45.90
1 120 40.00 47 35.30
2 60 20.00 18 13.50
3? 41 13.70 7 5.30
Mean ARR 1 year prior to switching 1.29 0.79 0.0002
95 % confidence interval 1.15–1.42 0.64–0.94
Standard deviation 1.19 0.9
Median 1 1
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Table 2 Clinical characteristics of propensity-matched cohorts of patients when switching to fingolimod or another iDMT therapy due to failure
of earlier iDMT therapy
Characteristics Fingolimod cohort (n = 99) iDMT cohort (n = 99) p value
Age when switching (years)
Mean 39.5 40.6
95 % confidence interval 37.6–41.3 38.6–42.7
Standard deviation 9.3 10.2
Median 39 40 0.4801
Gender (n, %)
Male 25 25.30 % 23 23.20 % 0.7401
Female 74 74.70 % 76 76.80 %
Days follow-up after switching (n, %)
180-359 11 11.10 % 4 4.00 %
360-719 36 36.40 % 9 9.10 %
720? 52 52.50 % 86 86.90 %
Mean 833.5 1242.3
95 % confidence interval 757.1–909.9 1153.9–1330.8
Standard deviation 383 443.4
Median 758 1238 \0.0001
Relapses
Proportion of patients with a relapse (n, %) 76 76.80 % 67 67.70 % 0.1533
Relapse in the 90 days prior to index 33 33.30 % 35 35.40 % 0.7647
Relapse in the 180 days prior to index 46 46.50 % 47 47.50 % 0.8868
Number of pre-index relapses, 1–360 days prior to index
0 38 38.40 % 41 41.40 %
1 41 41.40 % 38 38.40 %
2 16 16.20 % 13 13.10 %
3? 4 4.00 % 7 7.10 %
Mean 0.9 0.87 0.7158
95 % confidence interval 0.70–1.10 0.68–1.05































































Log-Rank test: Chi square
17.346 df 1.000, p value
\0.0001
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Table 3 Persistence on medication in the fingolimod and iDMT matched cohorts
Characteristics Fingolimod cohort (n = 99) Idmt cohort (n = 99) p value
Patients persistent (n, % yes) 82 82.80 % 47 47.50 % \0.0001
Patients discontinued therapy (n, %) 12 12.10 % 36 36.40 % \0.0001
Patient switched to another DMT (n, %) 5 5.10 % 16 16.20 % 0.0111
Reasons for discontinuation (n, % total population)
Insufficient efficacy 2 2.00 % 22 21.80 %
Side effects 10 9.90 % 16 15.80 %
Pregnancy/wish for child 1 1.00 % 2 2.00 %
Patient wish 3 3.00 % 6 5.90 %

























































Fig. 2 Time-to-relapse analysis
(Kaplan–Meier curves). Log-
Rank test: Chi square 4.982; df




























































Meier curves). Log-Rank test:
Chi square 2.484; df 1.000;
p value 0.115
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fingolimod 94 %, interferon b-1a (IFb-1a) 92 %], and
annualized relapse rate (NTD: fingolimod 0.21, iDMT
0.33; TRANSFORM [1]: fingolimod 0.16, IFb-1a 0.33).
Differences of results between this NTD cohort study and
the TRANSFORM study reflect that the NTD cohort
included RRMS patients with an unfavourable course
during earlier iDMT therapy, while TRANSFORMS with
IFb-1a as control group included patients independent of
previous course and medication.
These results can quantitatively support decision finding
processes in individual RRMS patients if iDMT therapy
fails. Accumulating evidence showing good cardiac safety
of fingolimod even in patients with preexisting cardiac
conditions [5] supports the benefit–risk considerations.
Enduring persistence on medication based on clinical
efficacy associated with good tolerability and safety leads
to a cost-effective allocation of health system resources in
favour of fingolimod compared to other DMTs [6, 7].
The impact of recent reports on PML in two patients
with fingolimod with no prior exposure to immunosup-
pressant drugs on the benefit–risk ratio of fingolimod is
under discussion as specific risk factors remain to be
identified and PML seems to be associated with a number
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Fig. 4 Proportion of patients
with various parameters of
clinical freedom of disease
activity in the matched cohort
treated with fingolimod or
iDMT after failure of earlier
iDMT therapy
Table 4 Relapses in the fingolimod and iDMT matched cohorts
Characteristics Fingolimod cohort (n = 99) iDMT cohort (n = 99) p value
Proportion of patients with relapse (n, %) 27 27.30 % 39 39.40 % 0.0704
Relapse within 90 days post switch 7 7.10 % 10 10.10 % 0.4467
Relapse within 180 days post switch 11 11.10 % 22 22.20 % 0.0359
Annualized relapse rate* (events/year) 0.21 0.33 0.0178*
95 % confidence interval 0.15–0.27 0.26–0.41
Number of relapses
0 72 72.70 % 60 60.60 %
1 16 16.20 % 21 21.20 %
2 7 7.10 % 9 9.10 %
3? 4 4.00 % 9 9.10 %
* Rate ratio (95 % CI) fingolimod vs iDMT: 0.63 (0.42, 0.93), p = 0.0178
Table 5 Cox proportional hazard models for matched patients with iDMT versus fingolimod therapy
Independent variables Coefficient Standard error Chi square p value Hazard ratio 95 % confidence interval
Index medication: BRACE vs fingolimod Lower limit Upper limit
Risk of medication discontinuation 1.113 0.281 15.665 \0.0001 3.044 1.754 5.282
Risk of relapse 0.554 0.251 4.854 0.028 1.739 1.063 2.846
Risk of EDSS progression 0.58 0.373 2.417 0.12 1.786 0.86 3.709
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